FDA Approves EVENITY™ (romosozumab-aqqg) For The Treatment Of Osteoporosis In Postmenopausal Women At High Risk For Fracture »

| Press Releases, BHOF in the News, Osteoporosis in the News

One in Two Women in the United States Will Suffer a Fracture in Her Lifetime Due to Osteoporosis(1) EVENITY is the First and Only Bone Builder With a Dual Effect That Both Increases Bone Formation and Decreases Bone Loss(2) EVENITY Rapidly Reduces Fracture Risk and Builds New Bone With 12 Months of Therapy(2) THOUSAND OAKS,… Read more »

Bindex Measurement Revolutionizes Osteoporosis Diagnostics in US »

| Osteoporosis in the News

Bone Index Ltd., a medical device company with game-changing point-of-care technology (BindexÂŽ) in osteoporosis diagnostics, announces that one million patients have been measured with BindexÂŽ in the U.S. in 2018. Earlier this year, the American Medical Association issued a new reimbursement code* for BindexÂŽ and the Centers for Medicare & Medicaid Services (CMS) has approved… Read more »

NPR Article: Wider Use Of Osteoporosis Drug Could Prevent Bone Fractures In More Elderly Women »

| BHOF in the News, Osteoporosis in the News

In response to a recent NPR article detailing the positive results of a common osteoporosis drug, Elizabeth Thompson, NOF, CEO, said:  “When the experts in the field say that this study is “extremely important”, “highly effective”, and “a breakthrough”, we are making progress! Reducing suffering and maintaining life quality is important for our senior population—key… Read more »

NOF Named an Official Charity Partner of the TCS New York City Marathon and Fields a Team of Runners Aged 40+ »

| BHOF in the News, Osteoporosis in the News, Press Releases

The National Osteoporosis Foundation (NOF), the leading bone health organization in the U.S., was named an Official Charity Partner of the 2018 TCS New York City Marathon. The race will take place on Sunday, November 4, 2018. For its inaugural team, NOF has secured five women over the age of 40 to join its Be… Read more »

Leading Organizations Meet To Discuss Unmet Needs In Osteoporosis and Outline An Initial Action Plan »

| BHOF in the News, Osteoporosis in the News, Press Releases

June 11, 2018| Press Releases On June 11, 2018, leaders from the National Osteoporosis Foundation (NOF), International Osteoporosis Foundation (IOF), and Amgen’s Bone Health and Advocacy Relations teams convened in London, England at the Royal Academy of Medicine. The purpose of the meeting was to develop a concrete plan for a meaningful collaboration between the two organizations. Back row:… Read more »

NOF Statement on New Treatment Option for Glucocorticoid-Induced Osteoporosis (GIOP) »

| BHOF in the News, Osteoporosis in the News

GIOP is the most common form of secondary osteoporosis. In the U.S., more than 10 percent of patients who receive long-term glucocorticoid treatment are diagnosed with a clinical fracture. The U.S. Food and Drug Administration (FDA) has recently approved the use of denosumab for the treatment of glucocorticoid-induced osteoporosis (GIOP) in men and women at… Read more »

NOF Response to JAMA Article Published December 26, 2017: The Association Between Calcium or Vitamin D Supplementation and Fracture Incidence in Community-Dwelling Older Adults: A Systematic Review and Meta-Analysis »

| Osteoporosis in the News, BHOF in the News

Approximately 10 million Americans over the age of 50 have osteoporosis, a condition that causes bones to become weak and more likely to break[i]. In fact, two million bone breaks occur every year in the U.S. due to osteoporosis, often resulting in immobility, pain, placement in a nursing home, isolation and other health problems. Scientific… Read more »